Lantus

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Sanofi
Lantus
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
Could This Drug News Give a Lift to Eli Lilly Stock?
Could This Drug News Give a Lift to Eli Lilly Stock?
Motley Fool
Eli Lilly
Rezvoglar
diabetes
Sanofi
Lantus
biosimilars
long-acting insulin
Flag link:
The mysterious case of Viatris and the missing insulin label deepens
The mysterious case of Viatris and the missing insulin label deepens
Fierce Pharma
Viatris
insulin
diabetes
biosimilars
Sanofi
Lantus
product recalls
Flag link:
Viatris launched two versions of its interchangeable insulin biosimilar. Why?
Viatris launched two versions of its interchangeable insulin biosimilar. Why?
Fierce Pharma
Biocon
Viatris
Semglee
insulin
biosimilars
diabetes
Sanofi
Lantus
Flag link:
FDA approves first interchangeable biosimilar
FDA approves first interchangeable biosimilar
Biopharma Reporter
FDA
biosimilars
interchangeable biosimilars
Semglee
Viatris
diabetes
insulin
Lantus
Flag link:
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
Fierce Pharma
ADA
diabetes
Novo Nordisk
insulin icodec
Sanofi
Lantus
insulin
Flag link:
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Motley Fool
FDA
Mylan
Biocon
Semglee
Sanofi
insulin
Lantus
diabetes
Flag link:
Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff
Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff
Fierce Pharma
Biocon
insulin
diabetes
Lantus
Mylan
drug manufacturing
Flag link:
Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning
Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning
Motley Fool
Sanofi
M&A
immuno-oncology
Lantus
diabetes
Flag link:
Novo and Sanofi make case for hypo-reducing insulins at EASD
Novo and Sanofi make case for hypo-reducing insulins at EASD
Pharmaforum
Novo Nordisk
Sanofi
EASD
diabetes
hypoglycemia
insulin
Lantus
Tresiba
Flag link:
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Fierce Pharma
Mylan
Lantus
generics
Biocon
drug manufacturing
diabetes
Flag link:
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?
Fierce Pharma
Merck
Samsung Bioepis
Lantus
insulin
diabetes
biosimilars
Mylan Labs
Biocon
Flag link:
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
Yahoo/Zacks.com
Mylan Labs
inter partes review
Sanofi
Lantus
patents
diabetes
Flag link:
Sanofi sues Mylan over Lantus patents, seeking to defend its top-selling drug
Sanofi sues Mylan over Lantus patents, seeking to defend its top-selling drug
Fierce Pharma
Sanofi
Mylan Labs
Lantus
patents
insulin
biosimilars
diabetes
Flag link:
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
Fierce Pharma
Sanofi
EASD
Toujeo
Lantus
hypoglycemia
diabetes
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
Sanofi brings another insulin glargine patent suit against Merck
Sanofi brings another insulin glargine patent suit against Merck
Drug Delivery Business News
Sanofi
patents
Merck
insulin glargine
Lantus
Flag link:

Pages